About medneo
medneo UK was founded by a group of experienced Radiographers and healthcare leaders with a vision for delivering a ‘best-in-class’ diagnostic imaging service – using modern technology and expert Radiographers skilled in advanced techniques and passionate about patient care.
27 February 2025 – medneo Announces Leadership Transition to Drive Next Phase of Growth
medneo UK has grown from a state-of-the-art London imaging centre to a highly regarded mobile scanning network, partnering with leading NHS Trusts across the UK to provide a complete turn-key solution to their imaging needs.
In five years, medneo UK has grown to be a successful operation with a significant fleet of modern MRI and CT trailers and an expertise that is unmatched outside the NHS.
People are at the heart of medneo’s success and the company employs a highly talented workforce of more than 130. They all share a passion for excellence in radiography and a commitment to improving timely access to high quality diagnostics.
Key facts
- 20 high-specification mobile scanning units (all new generation 14 MRI and 6 CT)
- State-of-the-art London imaging centre with 3T MRI, ultrasound and consulting rooms
- CQC Outstanding
- Great Place to Work for 3 years in a row (2021, 2022 and 2023)
- 99% patient satisfaction (Q4 2023 and Q1 2024)
CVC DIF
medneo is owned by CVC DIF (formerly DIF Capital Partners) is a leading global mid-market infrastructure equity fund manager. Founded in 2005 and headquartered in Amsterdam, the Netherlands, CVC DIF has c.€18 billion of infrastructure assets under management in energy transition, transport, utilities and digitalisation. With over 240 people in 12 offices, CVC DIF offers a unique market approach, combining a global presence with the benefits of strong local networks and sector-focused investment capabilities. CVC DIF acquired medneo in August 2024 and will support medneo with growth plans for the future.
medneo Announces Leadership Transition to Drive Next Phase of Growth
London, [3 March 2025] – medneo today announced a leadership transition that will see Andy Spellman step down as CEO, and Ella Tracey, the current COO, succeed him, effective 1 March 2025.
Since medneo was established by Andy Spellman in 2018, the company has grown into a leading provider of quality imaging services in the UK. This growth has been driven by a highly skilled team of directly employed radiographers, state-of-the-art mobile MRI and CT scanners, a focus on exceptional patient outcomes, and outstanding customer experience.
Ella Tracey, the incoming CEO, has a strong track record of scaling businesses, and is set to spearhead medneo’s ambitious growth strategy, supported by CVC DIF. Ella brings significant experience in private healthcare, having worked in CEO and Managing Director positions in oncology and fertility businesses including TFP Fertility, GenesisCare and OneStopDoctors. CVC DIF is the infrastructure strategy of CVC, a leading global private markets manager with
a global network of 30 offices and €200 billion of assets under management (as of 31 December 2024).
Andy Spellman, Founder/CEO medeno said: “I’ve given this a lot of thought, and I’ve decided the time is right for me to hand the baton over to Ella. My vision was to build a world-class imaging provider, and our success is testament to the commitment, professionalism, and hard work of the talented team at medneo. I’m immensely proud of all that we’ve achieved, and I wish Ella and the team every success on this next stage in the company’s growth journey.”
Steve Gray, Chair medeno commented: “Andy has led the company with a passion and commitment from a start-up to be the leader in quality imaging services. I want to thank him for all that he has done and for his continued support during this transition phase.
With Ella’s extensive experience in driving growth and transformation, improving commercial performance, and enhancing customer and people experience, I have no doubt medneo will thrive under her leadership supported by the significant investment and backing of CVC DIF.“
Ella Tracey, continued: “I’m excited and honoured to lead the incredibly talented team at medneo as we drive forward the company’s ambitions and growth strategy together. There is a huge opportunity for us to play an even bigger role in supporting the UK health system, working with our strategic partners including NHS Trusts and private providers and directly with consumers to improve patient health outcomes.”
Andy Spellman will remain as a Board Advisor, offering support and guidance for the future.
For further information email mary@maryoreilly.co.uk.
